Iron Deprivation Suppresses Hepatocellular Carcinoma Growth in Experimental Studies
文献类型:期刊论文
作者 | Ba, Qian2; Hao, Miao2; Huang, He1; Hou, Junmei2; Ge, Shichao2; Zhang, Zhuzhen2; Yin, Jun2; Chu, Ruiai2; Jiang, Hualiang1![]() |
刊名 | CLINICAL CANCER RESEARCH
![]() |
出版日期 | 2011-12-15 |
卷号 | 17期号:24页码:7625-7633 |
ISSN号 | 1078-0432 |
DOI | 10.1158/1078-0432.CCR-10-3099 |
文献子类 | Article |
英文摘要 | Purpose: Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related death, and iron overload is a significant risk factor in the development of HCC. In this study, we investigated the potential application of depriving iron by a novel iron chelator, thiosemicarbazone-24 (TSC24), in HCC treatment. Experimental Design: Two HCC cell lines and HFE knockout (HFE(-/-)) mice were used to determine iron chelation efficiency of TSC24. The anticancer effects of TSC24 on HCC were analyzed in vitro and in athymic xenograft mouse models. Results: Treatment with TSC24 significantly decreased the cellular iron concentration in hepatoma cells and the serum iron concentration in HFE(-/-) mice by blocking iron uptake and interfering with normal regulation of iron levels. Moreover, the viability of HCC cell lines was reduced by TSC24. Confirming the mechanism of the agent, this decrease in viability could be partially rescued by addition of exogenous iron. TSC24 also suppressed tumor growth in athymic mice bearing human HCC xenografts in a concentration-dependent manner, without apparent toxicity in parallel with a decrease in the serum iron level. Further studies revealed that TSC24 efficiently triggered cell-cycle arrest and apoptosis in Hep3B and HepG2 cell lines. Conclusions: TSC24 is a potent iron chelator that suppresses human HCC tumor growth by disrupting iron homeostasis, reducing available iron, and triggering cell-cycle arrest and apoptosis, without apparent host toxicity at effective doses. Thus, TSC24 shows great potential for the treatment of HCC. Clin Cancer Res; 17(24); 7625-33. (C)2011 AACR. |
WOS关键词 | TOPOISOMERASE II-ALPHA ; CELL-CYCLE ; CANCER ; OVERLOAD ; CHELATORS ; DISEASE ; HEMOCHROMATOSIS ; RISK ; CARCINOGENESIS ; PROLIFERATION |
资助项目 | Chinese Academy of Sciences[00000000] ; National Nature Science Foundation[81125020] ; National Nature Science Foundation[91029715] ; National Nature Science Foundation[31070680] ; National Nature Science Foundation[30870513] ; National Nature Science Foundation[81025017] ; Ministry of Science and Technology of China[2009CB919001] ; Ministry of Science and Technology of China[2012BAK01B04] ; Science and Technology Commission of Shanghai Municipality[08391910800] ; Science and Technology Commission of Shanghai Municipality[10391902100] ; Science and Technology Commission of Xuhui District of Shanghai Municipality[RCT201001] ; Science and Technology Commission of Xuhui District of Shanghai Municipality[CRC2010002] ; Director Foundation of INS[20090101] ; Food Safety Research Center[00000000] ; Key Laboratory of Nutrition and Metabolism of INS, SIBS, CAS[00000000] |
WOS研究方向 | Oncology |
语种 | 英语 |
WOS记录号 | WOS:000298410300014 |
出版者 | AMER ASSOC CANCER RESEARCH |
源URL | [http://119.78.100.183/handle/2S10ELR8/278302] ![]() |
专题 | 药物化学研究室 药物发现与设计中心 |
通讯作者 | Wang, Hui |
作者单位 | 1.Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China 2.Chinese Acad Sci, Inst Nutr Sci, Shanghai Inst Biol Sci, Key Lab Nutr & Metab, Shanghai 200031, Peoples R China; |
推荐引用方式 GB/T 7714 | Ba, Qian,Hao, Miao,Huang, He,et al. Iron Deprivation Suppresses Hepatocellular Carcinoma Growth in Experimental Studies[J]. CLINICAL CANCER RESEARCH,2011,17(24):7625-7633. |
APA | Ba, Qian.,Hao, Miao.,Huang, He.,Hou, Junmei.,Ge, Shichao.,...&Wang, Hui.(2011).Iron Deprivation Suppresses Hepatocellular Carcinoma Growth in Experimental Studies.CLINICAL CANCER RESEARCH,17(24),7625-7633. |
MLA | Ba, Qian,et al."Iron Deprivation Suppresses Hepatocellular Carcinoma Growth in Experimental Studies".CLINICAL CANCER RESEARCH 17.24(2011):7625-7633. |
入库方式: OAI收割
来源:上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。